natgillin/translations-raw huggingface dataset:
Of the 2,532 randomised intention-to-treat (ITT) patients, a total of 59 patients experienced at least one new vertebral fracture, placebo: 42 (3.37) – Preotact: 17 (1.32), p0.001.
Kokku 2532-st randomiseeritud ravikavatsuslikust (ITT – Intention-to-treat) patsiendist täheldati 59-l patsiendil uuringu käigus vähemalt ühte uut lülisamba murdu: 42-l patsiendil platseebogrupis (3,37%) ja 17-l patsiendil Preotact’i grupis (1,32%), p=0,001.
Of the 2,712 patients treated, 18% were ≥ 65 years of age, while 5% were ≥ 75 years of age.
Ravi saanud 2712 patsiendist oli 18% vanuses ≥ 65 aastat ning 5% olid vanuses ≥ 75 aastat.
Of the 208 bleeding episodes treated with Coagadex, 187 bleeding episodes in 15 subjects were evaluated for efficacy.
208 Coagadex’iga ravitud veritsemisepisoodist hinnati efektiivsuse suhtes 187 veritsemisepisoodi 15 uuringus osalejal.
Of the 21 CP CML patients treated with Bosulif following failure of imatinib and 1 additional second- generation TKI identified, 9 of these patients had MCyR or better including 2 patients with complete molecular response (CMR), 1 patient with major molecular response (MMR), 4 patients with CCyR, and 2 patients with partial cytogenetic response (PCyR) and had a treatment duration exceeding
21-st kroonilises faasis KML-iga patsiendist, keda raviti Bosulifiga pärast ravi ebaõnnestumist imatiniibi ja veel ühe teise põlvkonna TKI-ga, esines üheksal patsiendil MCyR või parem ravivastus, sealhulgas kaks patsienti täieliku molekulaarse ravivastusega (ingl complete molecular response, CMR), üks patsient olulise molekulaarse ravivastusega (ingl major molecular response, MMR), neli patsienti CCyR-iga ja kaks patsienti osalise tsütogeneetilise vastusega (ingl partial cytogenetic response, PCyR).
Of the 22 patients stable at week 8, 6 improved at week 12/16 and 4 deteriorated compared with baseline.
16. nädalal paranemise märke ning 4 seisund oli ravi algusega võrreldes halvenenud.
Of the 224 (26%) patients with reports of adverse reactions of anaemia, 5 patients discontinued bosutinib due to anaemia.
224-st (26%) aneemia kõrvaltoimega patsiendist viis katkestas ravi bosutiniibiga aneemia tõttu.
Of the 229 patients in the randomized study who received Abraxane monotherapy for breast cancer, 13% were at least 65 years of age and < 2% were 75 years and older.
229 patsiendist, kellele manustati Abraxane’i rinnavähi monoravina randomiseeritud uuringus, olid 13% vähemalt 65-aastased ja < 2% olid 75-aastased ja vanemad.
Of the 229 treated patients who were assessed for antibodies to Chinese hamster ovary (CHO) cell protein, 3 showed a statistically significant upward trend in titres, 4 displayed sustained peaks or transient spikes and one patient had both but no clinical symptoms.
229-st ravitud patsiendist, keda hinnati Hiina hamstri munasarja (CHO) rakuproteiini antikehade suhtes, ilmnes kolmel tiitrite statistiliselt oluline tõusutendents ning neljal püsivad või ajutised kõrgtasemed ja ühel patsiendil olid mõlemad, kuid puudusid kliinilised sümptomid.
Of the 230 patients randomised, 79 patients were assigned to Odomzo 200 mg.
230 randomiseeritud patsiendist 79 määrati saama Odomzo’t annuses 200 mg.
Of the 24 patients treated that had the NNRTI-associated K103N substitution pre-existing at baseline in their HIV-1, 22 maintained virologic suppression after switching to FTC/RPV/TDF.
24 ravi saanud patsiendist, kelle esines uuringu alguses HIV-1 isolaadis NNRTI-ga seotud K103N asendus, säilis 22 patsiendil viroloogiline supressioon ka pärast üleminekut FTC/RPV/TDF ravile.
Of the 249 bleeding episodes, the majority (211; 84.7%) were treated with 1-2 infusions.
249 verejooksujuhust enamikku (211 ehk 84,7%) raviti 1–2 infusiooniga.
Of the 26 patients without data available in the week 48 window, 7 patients discontinued due to adverse event or death, 16 patients discontinued for other reasons, and 3 patients were missing data but remained on study drug.
26-st patsiendist, kellel puudusid andmed 48. nädala andmete kogumise hetkel, 7 katkestasid kõrvaltoimete või surma tõttu, 16 katkestasid muudel põhjustel ja 3-l puudusid andmed, kuid nad jätkasid uuringuravimi võtmist.
Of the 26 placebo-treated patients, 13 patients subsequently crossed-over to receive siltuximab.
26-st platseeboravi saanud patsiendist 13 viidi hiljem ristuvalt üle siltuksimab-ravile.
Of the 29 major surgeries, 24 surgeries (82.8%) required a single pre-operative dose to maintain hemostasis during surgery.
29 ulatuslikust operatsioonist 24 puhul (82,8%) tuli manustada ühekordne preoperatiivne annus hemostaasi säilitamiseks kirurgilise operatsiooni ajal.
Of the 29 MCI subjects who had a positive PET scan, 19 (65.5%) were classified clinically as converted to clinical AD after 24 months compared to 0 (0%) of 16 who had a negative scan.
29-st positiivse PET-uuringu näiduga MCI-ga uuritavast 19 (65,5%) klassifitseeriti 24 kuu möödumisel kliiniliselt Alzheimeri tõvele üleläinuks; 16-st negatiivse näiduga patsiendist klassifitseeriti vastavalt 0 (0%) patsienti.
Of the 29 patients described above that were treated in Study CAC-002-01 3 patients discontinued (all due to AEs), and one patient died.
Kokku 29 eespool kirjeldatud patsiendist, keda raviti uuringus CAC-002-01, katkestas uuringu 3 patsienti (kõik kõrvalnähtude tõttu) ning 1 patsient suri.
Of the 29 patients described above that were treated in Study CAC-002-01 A total of 3patients discontinued (all due to AEs), and one patient died.
Kokku 29 eespool kirjeldatud patsiendist, keda raviti uuringus CAC-002-01, katkestas uuringu 3 patsienti (kõik kõrvalnähtude tõttu) ning 1 patsient suri.
Of the 3 cases consistent with LSCD, one case reported a positive dechallenge and no other concomitant drugs or comorbidity.
Neist kolmest juhust, mis olid kirjelduselt kokkusobivad limbaalsete tüvirakkude puudulikusega (LTRD), ühel juhul taandusid haigusnähud ravimi ärajätmisel ning puudusid teised samaaegselt kasutatavad ravimid või kaasuvad haigused.
Of the 3,430 plaque psoriasis patients exposed to Cosentyx in clinical studies, a total of 230 patients were 65 years of age or older and 32 patients were 75 years of age or older.
3430-st kliinilistes uuringutes Cosentyx’i saanud naastulise psoriaasiga patsientidest kokku 230 olid 65-aastased või vanemad ja 32 patsienti 75-aastased või vanemad.
Of the 32 inhibitor cases of the full patient cohort (n=101), 16 (16%) were classified as high titre (≥ 5 BU/mL) and 16 (16%) as low titre (< 5 BU/mL).
Kogu patsientide grupi (n = 101) 32 inhibiitorite tekkimise juhtumist 16 (16%) olid kõrge tiitriga (≥ 5 BÜ/ml) ja 16 (16%) madala tiitriga (< 5 BÜ/ml).
Of the 326 (38%) patients with reports of adverse reactions of thrombocytopenia, 29 (9%) patients discontinued treatment with bosutinib due to thrombocytopenia.
326-st (38%) trombotsütopeenia kõrvaltoimetega patsiendist 29 patsienti (9%) katkestas ravi bosutiniibiga trombotsütopeenia tõttu.
Of the 35 cases where medical history was provided, in 25 there was a history of bronchoconstrictive disease (asthma, COPD or bronchospasm) and in 10 there was no documented history of bronchoconstrictive disease, including 3 cases where the reporter explicitly stated that there was no history of asthma/bronchospasm/COPD.
35 juhust, mille puhul oli kättesaadav anamnees, esines selles 25 juhul bronhokonstriktiivne haigus (astma, KOK või bronhospasm) ja 10 juhul anamneesis dokumenteeritud bronhokonstriktiivset haigust ei esinenud, sealhulgas 3 juhul oli teates konkreetselt märgitud, et varem ei olnud astmat/bronhospasmi/KOK-i esinenud.
Of the 35 patients included in the efficacy analysis, 85.7% (95% CI: 69.7, 95.2) had a treatment response to XGEVA.
Efektiivsusanalüüsi kaasatud 35 patsiendist oli 85,7% (95% CI: 69,7; 95,2) ravivastus XGEVA’le.
Of the 361 women who received atosiban treatment in the phase III studies, 73 received at least one re- treatment, 8 received at least 2 re-treatments and 2 received 3 re-treatments (see section 4.4).
III faasi uuringus 361 naisest, kes said atosibaan-ravi, 73 said vähemalt ühe korduvravikuuri, 8 said vähemalt 2 korduvravikuuri ja 2 said 3 korduvravikuuri (vt lõik 4.4).
Of the 361 women who received atosiban treatment in the phase III studies, 73 received at least one re- treatment, 8 received at least 2 re-treatments and 2 received 3 re-treatments (see section 4.4).
III faasi uuringus 361 naisest, kes said atosibaanravi, 73 said vähemalt ühe korduvravikuuri, 8 said vähemalt 2 korduvravikuuri ja 2 said 3 korduvravikuuri (vt lõik 4.4).
Of the 39 patients who had received two or more prior induction regimens, 5 (13 %) [95 % CI: 4 %– 27 %] achieved a complete response (bone marrow blast counts ≤ 5 %, no other evidence of disease, and full recovery of peripheral blood counts) and 9 (23 %) [95 % CI: 11 %–39 %] achieved complete responses with or without full haematological recovery.
39-st kahte või enamat induktsioonravi skeemi saanud patsiendist 5 (13 %) [95 % CI: 4 %–27 %] saavutas täieliku ravivastuse (blastide arv luuüdis ≤ 5 %, muude haigustunnuste puudumine ja perifeerse vere rakkude arvu täielik taastumine) ja 9 (23 %) [95 % CI: 11 %–39 %] saavutas täieliku ravivastuse koos täieliku hematoloogilise paranemisega või ilma.
Of the 39 placebo subjects, 29 completed 24 months of treatment with Revestive.
39-st platseeborühmas osalejast 29 sai ravi Revestive’iga 24 kuud.
Of the 4,204 plaque psoriasis patients exposed to Taltz in clinical studies, a total of 301 were 65 years of age or older and 36 patients were 75 years of age or older.
4204-st kliinilistes uuringutes Taltz’iga ravi saanud naastulise psoriaasiga patsiendist kokku 301 olid 65-aastased või vanemad ning 36 patsienti 75-aastased või vanemad.
Of the 403 patients who received CRESEMBA in the Phase 3 studies, 79 (20%) of patients had an estimated glomerular filtration rate (GFR) less than 60 mL/min/1.73 m2.
403-st patsiendist, kes said III faasi uuringute vältel preparaati CRESEMBA, oli 79-l (20%) patsiendil hinnanguline glomerulaarfiltratsiooni kiirus (GFR) alla 60 ml/min/1,73 m2.
Of the 418 patients treated with Caelyx 50 mg/m2/cycle, and having a baseline measurement of left ventricular ejection fraction (LVEF) and at least one follow-up measurement assessed by MUGA scan, 88 patients had a cumulative anthracycline dose of > 400 mg/m2, an exposure level associated with an increased risk of cardiovascular toxicity with conventional doxorubicin.
418-st Caelyx’iga ravitud patsiendist, ravimi annuses 50 mg/m2/ravitsükli kohta, kellel oli enne ravi alustamist määratud südame vasema vatsakese väljutusfraktsioon ning jälgimisperioodil vähemalt ühel korral teostatud MUGA skaneerimine, oli 88-l patsiendil kumulatiivne antratsükliini annus > 400 mg/m2, st ekspositsioonitase, mis konventsionaalse doksorubitsiini korral on seotud suurenenud kardiovaskulaarse toksilisusega.
Of the 431 patients with pancreatic adenocarcinoma who were randomized to receive Abraxane in combination with gemcitabine, the majority (93%) were white, 4% were black and 2% were Asian.
431 pankrease adenokartsinoomiga patsiendist, kes randomiseeriti Abraxane’i ja gemtsitabiini kombinatsioonravi rühma, olid enamik (93%) valgenahalised, 4% mustanahalised ja 2% asiaadid.
Of the 449 patients in the clinical study of Iclusig, 155 (35%) were ≥ 65 years of age.
Iclusig’i kliinilises uuringus osalenud 449 patsiendist olid 155 (35%) vanuses ≥ 65 aastat.
Of the 452 patients randomized at baseline, the majority of patients were white (80.0% in the Chemo alone group and 75.3% in the Chemo+Avastin group), had squamous cell carcinoma (67.1% in the Chemo alone group and 69.6% in the Chemo+Avastin group), had persistent/recurrent disease (83.6% in the Chemo alone group and 82.8% in the Chemo+Avastin group), had 1-2 metastatic sites (72.0% in the Chemo alone group and 76.2% in the Chemo+Avastin group), had lymph node involvement (50.2% in the Chemo alone group and 56.4% in the Chemo+Avastin group), and had a platinum free interval  6 months (72.5% in the Chemo alone group and 64.4% in the Chemo+Avastin group).
452 randomiseeritud patsiendist enamik olid valge rassi esindajad (80,0% ainult kemoteraapia rühmas ja 75,3% kemoteraapia+Avastin’i rühmas), neil esines lamerakk-kartsinoom (67,1% ainult kemoteraapia rühmas ja 69,6% kemoteraapia+Avastin’i rühmas), püsiv/retsidiveerunud haigus (83,6% ainult kemoteraapia rühmas ja 82,8% kemoteraapia+Avastin’i rühmas), 1...2 metastaatilist paiget (72,0% ainult kemoteraapia rühmas ja 76,2% kemoteraapia+Avastin’i rühmas), lümfisõlmede haaratus (50,2% ainult kemoteraapia rühmas ja 56,4% kemoteraapia+Avastin’i rühmas) ning plaatinapreparaadi vaba intervall  6 kuud (72,5% ainult kemoteraapia rühmas ja 64,4% kemoteraapia+Avastin’i rühmas)
Of the 496 patients exposed to Kentera in the randomised, double-blind, placebo-controlled 12-week study and the 14-week safety extension study, 188 patients (38%) were 65 years of age and older.
496 patsiendist, kes kasutasid Kenterat 12-nädalases randomiseeritud topeltpimedas platseebokontrolliga uuringus ja 14-nädalases ohutuse jätku-uuringus, olid 188 patsienti (38%) 65- aastased ja vanemad.
Of the 497 patients who were treated with nivolumab 3 mg/kg every 2 weeks and evaluable for the presence of anti-product-antibodies, 51 (10.3%) patients tested positive for treatment-emergent anti-product antibodies by an electrochemiluminescent (ECL) assay.
497 patsiendist, kes said raviks nivolumabi 3 mg/kg iga 2 nädala järel ja kellel oli võimalik hinnata ravimivastaste antikehade olemasolu, oli 51 patsiendil (10,3%) elektrokemiluminestsents- analüüsil ravi ajal tekkinud ravimivastased antikehad positiivsed.
Of the 511 patients receiving ofatumumab in clinical trials, 300 patients (59%) experienced an infection.
Kliinilistes uuringutes ofatumumabi saanud 511 patsiendist 300-l (59%) tekkis infektsioon.
Of the 52 patients described above that were included in Study CAC-91-10-10 during the 17-year study period, 6 died, 3 had no evidence of treatment, 4 terminated the study, 10 were lost to follow-up, and for 1 data retrieval was unsuccessful.
Kokku 52 eespool kirjeldatud patsiendist, kes kaasati 17-aastase perioodi vältel uuringusse CAC-91- 10-10, suri 6 patsienti, 3 patsiendi ravi kohta puudusid tõendid, 4 patsienti katkestas uuringu, 10 patsienti kadusid järelkontrollist ning 1 patsiendi kohta ei õnnestunud saada andmeid.
Of the 52 patients described above that were included in Study CAC-91-10-10 during the 17-year study period, 6 died, 3had no evidence of treatment, 4 terminated the study, 10 were lost to follow-up, and for 1 data retrieval was unsuccessful.
Kokku 52 eespool kirjeldatud patsiendist, kes kaasati 17-aastase perioodi vältel uuringusse CAC-91- 10-10, suri 6 patsienti, 3 patsiendi ravi kohta puudusid tõendid, 4 patsienti katkestas uuringu, 10 patsienti kadusid järelkontrollist ning 1 patsiendi kohta ei õnnestunud saada andmeid.
Of the 52 patients identified, 36 patients were in the CP CML subpopulation (21 who had previously received 2 prior TKIs and 15 who had received 1 prior TKI).
52-st tuvastatud patsiendist 36 kuulusid kroonilises faasis KML-iga alapopulatsiooni (21 olid varem saanud ravi kahe TKI-ga ja 15 olid varem saanud ravi ühe TKI-ga).
Of the 54 patients withdrawn from ORENCIA during the double-blind period for up to 6 months, none had an infusion reaction upon re-initiation of ORENCIA.
Uuringu topeltpimedal perioodil kuni kuue kuu jooksul ORENCIA ravist eemaldatud 54 patsiendist mitte kellegil ei ilmnenud infusioonist tingitud reaktsioone ORENCIA ravi taasalustamisel.
Of the 540 patients in, 61% were male, 43% were ≥ 65 years (median age was 62 years [range 15-89]) and 98% were white.
540 patsiendist 61% olid mehed, 43% 65-aastased või vanemad (mediaanvanus oli 62 aastat (vahemik 15…89)) ja 98% olid valge rassi esindajad.
Of the 571 ankylosing spondylitis patients exposed to Cosentyx in clinical studies, a total of 24 patients were 65 years of age or older and 3 patients were 75 years of age or older.
571-st kliinilistes uuringutes Cosentyx’i saanud anküloseeriva spondüliidiga patsiendist kokku 24 olid 65-aastased või vanemad ja 3 patsienti 75-aastased või vanemad.
Of the 6026 total number of patients in clinical studies of Repatha, 1779 (30%) were ≥ 65 years old, while 223 (4%) were ≥ 75 years old.
Repatha kliinilistes uuringutes osales kokku 6026 patsienti, kellest 1779 (30%) olid ≥ 65-aastased ning 223 (4%) olid ≥ 75-aastased.
Of the 611 patients treated with the ZALTRAP/FOLFIRI regimen in the pivotal study of MCRC patients, 172 (28.2%) were aged ≥65 and <75 and 33 (5.4%) were age ≥75.
Olulise tähtsusega mKRK uuringu ZALTRAP/FOLFIRI raviskeemi 611 patsiendist olid 172 patsienti (28,2%) ≥65...<75-aastased ning 33 (5,4%) olid ≥75-aastased.
Of the 681 (78%) patients that experienced diarrhoea, 665 patients had drug-related events of diarrhoea and 8 patients discontinued bosutinib due to this event.
681-st (78%) kõhulahtisusega patsiendist esinesid 665 patsiendil ravimiga seotud kõhulahtisuse juhud ja kaheksa patsienti katkestas selle tõttu ravi bosutiniibiga.
Of the 704 patients evaluated in the MM-009 and MM-010 studies, 44.6% were aged 65 or over.
704-st MM-009 ja MM-010 uuringutes hinnatud patsiendist olid 44,6% 65-aastased või vanemad.
Of the 72 patients randomised to Cosentyx 150 mg, 45 and 35 had an ASAS 20/40 response, respectively.
72-st Cosentyx 150 mg rühma randomiseeritud patsientidest 45 ja 35 saavutasid vastavalt ASAS 20/40 ravivastuse.
Of the 760 randomised patients, the median age was 61 years, 61% were male, 78% were Caucasian, and all patients had baseline ECOG Performance Status (PS) of 0 or 1.
760 randomiseeritud patsiendi keskmine vanus oli 61 aastat, mehi oli 61%, heledanahalisi 78% ja kõigil patsientidel oli ECOG skoori alusel algne üldseisund (Performance Status – PS) 0 või 1.
Of the 783 patients initially randomised to active treatment in RA-I, 508 completed 52 weeks of placebo- controlled treatment and entered the open-label extension study.
783-st aktiivravi uuringusse RA-I randomiseeritud patsiendist sai 52 nädalat platseebo-ravi 508 patsienti ja nad võeti vastu avatud jätku-uuringusse.
Of the 87 patients treated with Epclusa + RBV, 85 patients were included in the analysis of NS5A RAVs; 2 patients were excluded as they neither achieved SVR12 nor had virologic failure.
87-st Epclusaga + RBV-ga ravitud patsiendist 85 kaasati NS5A RAV-ide analüüsimisse; 2 patsienti välistati, kuna neil ei tekkinud ei SVR12 ega ka viroloogilise ravivastuse puudumine.
Of the 97 aMCI patients who had a positive PET scan and at least one committee assessment, 52 (54%) were classified clinically as converted to clinical AD after 36 months compared to 29 (23%) of 127 who had a negative scan and at least one committee assessment.
97-st positiivse PET-skaneeringu näidu ja vähemalt ühe komisjoni hinnanguga aMCI-ga patsiendist 52 (54%) klassifitseeriti 36 kuu möödumisel kliiniliselt Alzheimeri tõvele üleläinuks; 127-st negatiivse PET-skaneeringu näidu ja vähemalt ühe komisjoni hinnanguga aMCI-ga patsiendist klassifitseeriti vastavalt 29 (23%) patsienti.
Of the 974 psoriatic arthritis patients exposed to Cosentyx in clinical studies, a total of 85 patients were 65 years of age or older and 4 patients were 75 years of age or older.
974-st kliinilistes uuringutes Cosentyx’i saanud psoriaatilise artriidiga patsiendist kokku 85 olid 65-aastased või vanemad ja 4 patsienti 75-aastased või vanemad.
Of the 981 patients treated with IMBRUVICA for B-cell malignancies, 5% discontinued treatment primarily due to adverse reactions.
981-st IMBRUVICA-ravi B-rakuliste pahaloomuliste kasvajate vastu saanud patsiendist katkestas ravi peamiselt kõrvaltoimete tõttu 5%.
Of the 981 patients treated with IMBRUVICA, 62% were 65 years of age or older.
981-st IMBRUVICA-ravi saanud patsiendist 62% olid 65-aastased või vanemad.
Of the CP-CML patients previously treated with one, two, three or four prior TKIs, 75% (12/16), 67% (66/98), 45% (64/141), and 58% (7/12)) achieved a MCyR while on Iclusig, respectively.
Kroonilises faasis kroonilise müeloidse leukeemiaga patsientidest, keda oli varem ravitud ühe, kahe, kolme või nelja türosiinkinaasi inhibiitorite raviskeemiga, saavutati Iclusig-raviga vastavalt oluline tsütogeneetiline ravivastus 75% (12/16), 67% (66/98), 45% (64/141) ja 58% (7/12).
Of the hepatic AEs, increased ALT and AST were the most common events and the majority were either Grade 1 or 2.
Maksa kõrvaltoimetest kõige sagedamini esines ALAT ja ASAT aktiivsuse suurenemist ning enamik olid kas 1. või 2. raskusastme juhud.
of the herbal preparation St John’s
naistepuna (Hypericum
Of the HIV-1 isolates from 10 patients with resistance development in the Genvoya group, the mutations that emerged were M184V/I (n = 9) and K65R/N (n = 2) in RT and T66T/A/I/V (n = 2), E92Q (n = 4), Q148Q/R (n = 1) and N155H (n = 2) in integrase.
10-l Genvoya rühma kuulunud väljakujuneva resistentsusega patsiendil tekkisid HIV-1 isolaatide mutatsioonid M184V/I (n = 9) ja K65R/N (n = 2) pöördtranskriptaasis ning T66T/A/I/V (n = 2), E92Q (n = 4), Q148Q/R (n = 1) ja N155H (n = 2) integraasis.
Of the HIV-1 isolates from 8 patients with resistance development in the E/C/F/TDF group, the mutations that emerged were M184V/I (n = 6) and K65R/N (n = 3) in RT and E92E/Q (n = 2), and Q148R (n = 2), and N155H/S (n = 2) in integrase.
8-l E/C/F/TDF rühma kuulunud väljakujuneva resistentsusega patsiendil tekkisid HIV-1 isolaatide mutatsioonid M184V/I (n = 6) ja K65R/N (n = 3) pöördtranskriptaasis ning E92E/Q (n = 2), Q148Q/R (n = 2) ja N155H/S (n = 2) integraasis.
Of the infliximab- treated patients who received at least one shortened infusion, infusion-related reactions occurred in 15% of patients and serious infusion reactions occurred in 0.4% of patients.
Infliksimabravi saanud patsientidel, kes said vähemalt ühe lühendatud infusiooni, ilmnes infusiooniga seotud reaktsioone 15%-l patsientidest ning tõsiseid infusioonireaktsioone esines 0,4%-l patsientidest.
of the methadone dose may be
kasutamisel olla vajalik metadooni
Of the most commonly reported, the following events occurred more often with Ranexa (placebo-corrected frequencies) in elderly ( 75 years of age) than younger patients (< 75 years of age): constipation (8% versus 5%), nausea (6% versus 3%), hypotension (5% versus 1%), and vomiting (4% versus 1%).
Kõige sagedamini Ranexa kasutamisel esinenud kõrvaltoimetest (platseeboga korrigeeritud sagedused) esinesid eakatel ( 75 aastat) sagedamini kui noorematel patsientidel (< 75 aastat) järgmised kõrvaltoimed: kõhukinnisus (8%, võrreldes 5%-ga), iiveldus (6%, võrreldes 3%-ga), hüpotensioon (5%, võrreldes 1%-ga) ja oksendamine (4%, võrreldes 1%-ga).
Of the need for the procedures/tests before and during teriflunomide treatment
protseduuride ja laboratoorsete uuringute vajadus enne ravi ja ravi ajal teriflunomiidiga,
Of the other 4 cases, detailed information was missing.
Ülejäänud neljal juhul detailne informatsioon puudus.
Of the patients enrolled in the study 10 patients on vandetanib and 4 on placebo (4% of all patients) had a World Health Organization performance status (WHO PS) score of ≥ 2 and 28 (12.1%) patients on vandetanib and 10 (10.1%) on placebo had cardiac impairment.
Uuringusse kaasatud patsientidest esines 10-l vandetaniibi ja 4-l platseebo patsiendil (4% kõigist patsientidest) Maailma Terviseorganisatsiooni sooritus-staatuse (WHO PS) skoor ≥ 2; 28-l (12,1%) vandetaniibi patsiendil ja 10-l (10,1%) platseebo patsiendil esines südamekahjustus.
Of the patients originally receiving methotrexate alone, 81 % received MabThera either as rescue between weeks 16-24 or in the extension trial, before week 56.
Alguses ainult metotreksaati saanud patsientidest 81 % said MabThera’t abiravimina nädalatel 16…24 või jätku-uuringu raames enne 56. nädalat.
Of the patients randomised to the chemotherapy arm, 48% crossed over and subsequently received treatment with pembrolizumab.
Kemoteraapia rühma randomiseeritud patsientidest 48% viidi üle ning said järgnevalt ravi pembrolizumabiga.